ROCHESTER, N.Y., July 8 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a provider of quantitative imaging for clinical trials, today announced revenues for the second quarter ended June 30, 2009 exceeded $2.5 million, representing a greater than 45% increase over the comparable period in 2008.
"We are extremely pleased to deliver another quarter of record revenue growth," stated Jeff Markin, President and Chief Executive Officer of VirtualScopics, Inc. "Our strong second quarter coupled with our solid financial performance in the first quarter, has resulted in top line growth of nearly 40% for the first six months of 2009." He added, "The continued demand we're seeing from our customers gives us confidence that we are on track to meet our financial targets for the remainder of 2009."
VirtualScopics plans to report its complete second quarter 2009 financial results on Wednesday, August 12, 2009. Jeff Markin and Molly Henderson, VirtualScopics' Chief Business and Financial Officer, will provide a business update and discuss the second quarter results during the conference call on Thursday, August 13, 2009 at 11:00 a.m. EDT.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit
|SOURCE VirtualScopics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved